Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-20-000032
Filing Date
2020-05-06
Accepted
2020-05-06 16:10:01
Documents
43
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sava-20200331x10q.htm 10-Q 731634
2 EX-31.1 sava-20200331xex31_1.htm EX-31.1 25477
3 EX-31.2 sava-20200331xex31_2.htm EX-31.2 25037
4 EX-32.1 sava-20200331xex32_1.htm EX-32.1 20292
  Complete submission text file 0001069530-20-000032.txt   2710468

Data Files

Seq Description Document Type Size
5 EX-101.INS sava-20200331.xml EX-101.INS 488488
6 EX-101.SCH sava-20200331.xsd EX-101.SCH 23792
7 EX-101.CAL sava-20200331_cal.xml EX-101.CAL 23512
8 EX-101.DEF sava-20200331_def.xml EX-101.DEF 57703
9 EX-101.LAB sava-20200331_lab.xml EX-101.LAB 175016
10 EX-101.PRE sava-20200331_pre.xml EX-101.PRE 145626
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 20852687
SIC: 2834 Pharmaceutical Preparations